Park Avenue Securities LLC bought a new position in shares of Vericel Co. (NASDAQ:VCEL – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,042 shares of the biotechnology company’s stock, valued at approximately $262,000.
Several other institutional investors have also recently made changes to their positions in VCEL. DekaBank Deutsche Girozentrale purchased a new position in shares of Vericel during the fourth quarter worth $33,000. GAMMA Investing LLC acquired a new stake in Vericel during the fourth quarter valued at $65,000. Sentry Investment Management LLC acquired a new stake in Vericel during the fourth quarter valued at $136,000. PNC Financial Services Group Inc. grew its position in Vericel by 8.1% during the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 344 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Vericel during the fourth quarter valued at $197,000.
Vericel Trading Down 1.9 %
VCEL opened at $45.03 on Tuesday. The firm has a market capitalization of $2.19 billion, a PE ratio of -4,498.50 and a beta of 1.70. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $53.05. The firm’s 50-day moving average price is $46.58 and its 200 day moving average price is $44.62.
Insider Activity
In other news, insider Sean C. Flynn sold 6,772 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the sale, the insider now directly owns 487 shares of the company’s stock, valued at approximately $21,924.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Sean C. Flynn sold 1,474 shares of Vericel stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $45.84, for a total value of $67,568.16. Following the completion of the transaction, the insider now owns 487 shares in the company, valued at $22,324.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sean C. Flynn sold 6,772 shares of Vericel stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $45.02, for a total transaction of $304,875.44. Following the completion of the transaction, the insider now owns 487 shares of the company’s stock, valued at approximately $21,924.74. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,246 shares of company stock valued at $1,924,869. Company insiders own 7.20% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently commented on VCEL. HC Wainwright raised their price target on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday, June 21st. Truist Financial restated a “buy” rating and set a $54.00 price target on shares of Vericel in a research report on Tuesday, March 26th. Finally, TD Cowen started coverage on shares of Vericel in a research report on Thursday, June 20th. They issued a “buy” rating and a $55.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $48.17.
Check Out Our Latest Report on Vericel
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Featured Articles
- Five stocks we like better than Vericel
- What Are the FAANG Stocks and Are They Good Investments?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- About the Markup Calculator
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Comparing and Trading High PE Ratio Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Co. (NASDAQ:VCEL – Free Report).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.